DB
KPTI icon

Dmitry Balyasny’s Karyopharm Therapeutics KPTI Stock Holding History

Dmitry Balyasny’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$557K – 3274
2026
Q1 		$557K Buy
+100,000
New +$762K ﹤0.01% 2324

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dmitry Balyasny's KPTI Position: Q2 2026 in Review

Dmitry Balyasny sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 70,748 shares — an estimated $394K sold.

Dmitry Balyasny first reported a position in KPTI in Q3 2014 and held it in 16 quarters. The position peaked at $5.61M in Q4 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Dmitry Balyasny reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 70,748 Karyopharm Therapeutics shares in Q2 2026, an estimated $394K.
  • Dmitry Balyasny first reported a position in Karyopharm Therapeutics in Q3 2014 and held it in 16 quarters.
  • Dmitry Balyasny's Karyopharm Therapeutics position peaked at $5.61M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.